New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ADI;CTRX;DISCA;EQIX;LBTYA;LMCA;REGN;SBAC;VRSK;WDC From The Last 14 Days
Check below for free stories on ADI;CTRX;DISCA;EQIX;LBTYA;LMCA;REGN;SBAC;VRSK;WDC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
September 4, 2014
07:58 EDTADIAnalog Devices shares look attractive after decline, says Argus
Subscribe for More Information
06:46 EDTVRSKVerisk Analytics' Touchstone platform selected by Fermat
Subscribe for More Information
05:37 EDTREGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 3, 2014
09:00 EDTEQIXEquinix Cogent should be bought at current levels, says Pacific Crest
Pacific Crest expects Equinix and Cogent to benefit from an accelerating trend of enterprises moving to the cloud.
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use